TY - JOUR
T1 - A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma
AU - Richardson, Paul G.
AU - Blood, Emily
AU - Mitsiades, Constantine S.
AU - Jagannath, Sundar
AU - Zeldenrust, Steven R.
AU - Alsina, Melissa
AU - Schlossman, Robert L.
AU - Rajkumar, S. Vincent
AU - Desikan, K. Raman
AU - Hideshima, Teru
AU - Munshi, Nikhil C.
AU - Kelly-Colson, Kathleen
AU - Doss, Deborah
AU - McKenney, Mary L.
AU - Gorelik, Svetlana
AU - Warren, Diane
AU - Freeman, Andrea
AU - Rich, Rebecca
AU - Wu, Anfang
AU - Olesnyckyj, Marta
AU - Wride, Kenton
AU - Dalton, William S.
AU - Zeldis, Jerome
AU - Knight, Robert
AU - Weller, Edie
AU - Anderson, Kenneth C.
PY - 2006/11/15
Y1 - 2006/11/15
N2 - This multicenter, open-label, randomized phase 2 study evaluated 2 dose regimens of lenalidomide for relapsed, refractory myeloma. Seventy patients were randomized to receive either 30 mg once-daily or 15 mg twice-daily oral lenalidomide for 21 days of every 28-day cycle. Patients with progressive or stable disease after 2 cycles received dexamethasone. Analysis of the first 70 patients showed increased grade 3/4 myelosuppression in patients receiving 15 mg twice daily (41% versus 13%, P = .03). An additional 32 patients received 30 mg once daily. Responses were evaluated according to European Group for Blood and Marrow Transplantation (EBMT) criteria. Overall response rate (complete, partial, or minor) to lenalidomide alone was 25% (24% for once-daily and 29% for twice-daily lenalidomide). Median overall survival in 30-mg once-daily and twice-daily groups was 28 and 27 months, respectively. Median progression-free survival was 7.7 months on once-daily versus 3.9 months on twice-daily lenalidomide (P = .2). Dexamethasone was added in 68 patients and 29% responded. Time to first occurrence of clinically significant grade 3/4 myelosuppression was shorter in the twice-daily group (1.8 vs 5.5 months, P = .05). Significant peripheral neuropathy and deep vein thrombosis each occurred in only 3%. Lenalidomide is active and well tolerated in relapsed, refractory myeloma, with the 30-mg once-daily regimen providing the basis for future studies as monotherapy and with dexamethasone.
AB - This multicenter, open-label, randomized phase 2 study evaluated 2 dose regimens of lenalidomide for relapsed, refractory myeloma. Seventy patients were randomized to receive either 30 mg once-daily or 15 mg twice-daily oral lenalidomide for 21 days of every 28-day cycle. Patients with progressive or stable disease after 2 cycles received dexamethasone. Analysis of the first 70 patients showed increased grade 3/4 myelosuppression in patients receiving 15 mg twice daily (41% versus 13%, P = .03). An additional 32 patients received 30 mg once daily. Responses were evaluated according to European Group for Blood and Marrow Transplantation (EBMT) criteria. Overall response rate (complete, partial, or minor) to lenalidomide alone was 25% (24% for once-daily and 29% for twice-daily lenalidomide). Median overall survival in 30-mg once-daily and twice-daily groups was 28 and 27 months, respectively. Median progression-free survival was 7.7 months on once-daily versus 3.9 months on twice-daily lenalidomide (P = .2). Dexamethasone was added in 68 patients and 29% responded. Time to first occurrence of clinically significant grade 3/4 myelosuppression was shorter in the twice-daily group (1.8 vs 5.5 months, P = .05). Significant peripheral neuropathy and deep vein thrombosis each occurred in only 3%. Lenalidomide is active and well tolerated in relapsed, refractory myeloma, with the 30-mg once-daily regimen providing the basis for future studies as monotherapy and with dexamethasone.
UR - http://www.scopus.com/inward/record.url?scp=33750607347&partnerID=8YFLogxK
U2 - 10.1182/blood-2006-04-015909
DO - 10.1182/blood-2006-04-015909
M3 - Article
C2 - 16840727
AN - SCOPUS:33750607347
SN - 0006-4971
VL - 108
SP - 3458
EP - 3464
JO - Blood
JF - Blood
IS - 10
ER -